These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 35983412)

  • 1. Incomplete Penetrance and Variable Expressivity: From Clinical Studies to Population Cohorts.
    Kingdom R; Wright CF
    Front Genet; 2022; 13():920390. PubMed ID: 35983412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incomplete penetrance and variable expressivity in monogenic diabetes; a challenge but also an opportunity.
    Li M; Popovic N; Wang Y; Chen C; Polychronakos C
    Rev Endocr Metab Disord; 2023 Aug; 24(4):673-684. PubMed ID: 37165203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of penetrance and variable expressivity in monogenic metabolic conditions across 77,184 exomes.
    Goodrich JK; Singer-Berk M; Son R; Sveden A; Wood J; England E; Cole JB; Weisburd B; Watts N; Caulkins L; Dornbos P; Koesterer R; Zappala Z; Zhang H; Maloney KA; Dahl A; Aguilar-Salinas CA; Atzmon G; Barajas-Olmos F; Barzilai N; Blangero J; Boerwinkle E; Bonnycastle LL; Bottinger E; Bowden DW; Centeno-Cruz F; Chambers JC; Chami N; Chan E; Chan J; Cheng CY; Cho YS; Contreras-Cubas C; Córdova E; Correa A; DeFronzo RA; Duggirala R; Dupuis J; Garay-Sevilla ME; García-Ortiz H; Gieger C; Glaser B; González-Villalpando C; Gonzalez ME; Grarup N; Groop L; Gross M; Haiman C; Han S; Hanis CL; Hansen T; Heard-Costa NL; Henderson BE; Hernandez JMM; Hwang MY; Islas-Andrade S; Jørgensen ME; Kang HM; Kim BJ; Kim YJ; Koistinen HA; Kooner JS; Kuusisto J; Kwak SH; Laakso M; Lange L; Lee JY; Lee J; Lehman DM; Linneberg A; Liu J; Loos RJF; Lyssenko V; Ma RCW; Martínez-Hernández A; Meigs JB; Meitinger T; Mendoza-Caamal E; Mohlke KL; Morris AD; Morrison AC; Ng MCY; Nilsson PM; O'Donnell CJ; Orozco L; Palmer CNA; Park KS; Post WS; Pedersen O; Preuss M; Psaty BM; Reiner AP; Revilla-Monsalve C; Rich SS; Rotter JI; Saleheen D; Schurmann C; Sim X; Sladek R; Small KS; So WY; Spector TD; Strauch K; Strom TM; Tai ES; Tam CHT; Teo YY; Thameem F; Tomlinson B; Tracy RP; Tuomi T; Tuomilehto J; Tusié-Luna T; van Dam RM; Vasan RS; Wilson JG; Witte DR; Wong TY; ; Burtt NP; Zaitlen N; McCarthy MI; Boehnke M; Pollin TI; Flannick J; Mercader JM; O'Donnell-Luria A; Baxter S; Florez JC; MacArthur DG; Udler MS
    Nat Commun; 2021 Jun; 12(1):3505. PubMed ID: 34108472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rare genetic variants in genes and loci linked to dominant monogenic developmental disorders cause milder related phenotypes in the general population.
    Kingdom R; Tuke M; Wood A; Beaumont RN; Frayling TM; Weedon MN; Wright CF
    Am J Hum Genet; 2022 Jul; 109(7):1308-1316. PubMed ID: 35700724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Penetrance and expressivity in the molecular age.
    Zlotogora J
    Genet Med; 2003; 5(5):347-52. PubMed ID: 14501829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the Pathogenicity, Penetrance, and Expressivity of Putative Disease-Causing Variants in a Population Setting.
    Wright CF; West B; Tuke M; Jones SE; Patel K; Laver TW; Beaumont RN; Tyrrell J; Wood AR; Frayling TM; Hattersley AT; Weedon MN
    Am J Hum Genet; 2019 Feb; 104(2):275-286. PubMed ID: 30665703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An increased burden of rare exonic variants in NRXN1 microdeletion carriers is likely to enhance the penetrance for autism spectrum disorder.
    Cameli C; Viggiano M; Rochat MJ; Maresca A; Caporali L; Fiorini C; Palombo F; Magini P; Duardo RC; Ceroni F; Scaduto MC; Posar A; Seri M; Carelli V; Visconti P; Bacchelli E; Maestrini E
    J Cell Mol Med; 2021 Mar; 25(5):2459-2470. PubMed ID: 33476483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incomplete penetrance and variable expressivity: is there a microRNA connection?
    Ahluwalia JK; Hariharan M; Bargaje R; Pillai B; Brahmachari V
    Bioessays; 2009 Sep; 31(9):981-92. PubMed ID: 19642110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Penetrance and Expressivity in Inherited Cancer Predisposing Syndromes.
    Taeubner J; Wieczorek D; Yasin L; Brozou T; Borkhardt A; Kuhlen M
    Trends Cancer; 2018 Nov; 4(11):718-728. PubMed ID: 30352675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidance for estimating penetrance of monogenic disease-causing variants in population cohorts.
    Wright CF; Sharp LN; Jackson L; Murray A; Ware JS; MacArthur DG; Rehm HL; Patel KA; Weedon MN
    Nat Genet; 2024 Sep; 56(9):1772-1779. PubMed ID: 39075210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of incomplete penetrance and variable expressivity in heritable cardiac arrhythmia syndromes.
    Giudicessi JR; Ackerman MJ
    Transl Res; 2013 Jan; 161(1):1-14. PubMed ID: 22995932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Penetrance and expressivity of genes involved in the development of epilepsy in the genetically epilepsy-prone rat (GEPR).
    Kurtz BS; Lehman J; Garlick P; Amberg J; Mishra PK; Dailey JW; Weber R; Jobe PC
    J Neurogenet; 2001; 15(3-4):233-44. PubMed ID: 12092906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polygenic risk affects the penetrance of monogenic kidney disease.
    Khan A; Shang N; Nestor JG; Weng C; Hripcsak G; Harris PC; Gharavi AG; Kiryluk K
    medRxiv; 2023 May; ():. PubMed ID: 37214819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Penetrance, variable expressivity and monogenic neurodevelopmental disorders.
    de Masfrand S; Cogné B; Nizon M; Deb W; Goldenberg A; Lecoquierre F; Nicolas G; Bournez M; Vitobello A; Mau-Them FT; le Guyader G; Bilan F; Bauer P; Zweier C; Piard J; Pasquier L; Bézieau S; Gerard B; Faivre L; Saugier-Veber P; Piton A; Isidor B
    Eur J Med Genet; 2024 Jun; 69():104932. PubMed ID: 38453051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotype and Genotype Correlations in Inherited Retinal Diseases: Population-Guided Variant Interpretation, Variable Expressivity and Incomplete Penetrance.
    Ellingford JM; Hufnagel RB; Arno G
    Genes (Basel); 2020 Oct; 11(11):. PubMed ID: 33137882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incomplete penetrance in primary immunodeficiency: a skeleton in the closet.
    Gruber C; Bogunovic D
    Hum Genet; 2020 Jun; 139(6-7):745-757. PubMed ID: 32067110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variability in Gene Expression is Associated with Incomplete Penetrance in Inherited Eye Disorders.
    Green DJ; Sallah SR; Ellingford JM; Lovell SC; Sergouniotis PI
    Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32050448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance and translational impact of reduced penetrance in genetic movement disorders.
    Heinzel S; Mascalzoni D; Bäumer T; Berg D; Kasten M; Brüggemann N
    Med Genet; 2022 Jun; 34(2):151-156. PubMed ID: 38835915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Penetrance and expressivity of mitochondrial variants in a large clinically unselected population.
    Cannon SJ; Hall T; Hawkes G; Colclough K; Boggan RM; Wright CF; Pickett SJ; Hattersley AT; Weedon MN; Patel KA
    Hum Mol Genet; 2024 Feb; 33(5):465-474. PubMed ID: 37988592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clustering of predicted loss-of-function variants in genes linked with monogenic disease can explain incomplete penetrance.
    Beaumont RN; Hawkes G; Gunning AC; Wright CF
    Genome Med; 2024 Apr; 16(1):64. PubMed ID: 38671509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.